# Article information:

A clinician’s handbook for using ctDNA throughout the patient journey
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935823/>

# Article summary:

1. Cell-free DNA (ctDNA) is a promising biomarker for cancer diagnosis and treatment.

2. ctDNA can be used to detect genetic alterations in tumors, monitor tumor evolution, and assess patient outcomes with genotype-matched clinical trials.

3. Recent studies have demonstrated the high concordance between ctDNA and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article provides an overview of the use of cell-free DNA (ctDNA) as a biomarker for cancer diagnosis and treatment throughout the patient journey. The article cites several studies that demonstrate the potential of ctDNA to detect genetic alterations in tumors, monitor tumor evolution, and assess patient outcomes with genotype-matched clinical trials. The article also discusses recent studies that have demonstrated the high concordance between ctDNA and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer.

The article is generally reliable and trustworthy, as it cites multiple peer-reviewed studies to support its claims. However, there are some potential biases that should be noted. For example, the article does not discuss any potential risks associated with using ctDNA as a biomarker or any possible limitations of this approach. Additionally, while the article does mention some counterarguments to using ctDNA as a biomarker, it does not explore them in depth or provide evidence to support them. Furthermore, while the article does present both sides of the argument equally, it could benefit from providing more detail on each side's arguments and evidence for their claims. Finally, there is no promotional content included in the article which could indicate bias towards one side or another.

In conclusion, while this article is generally reliable and trustworthy due to its citation of multiple peer reviewed studies, there are some potential biases that should be noted such as lack of discussion on potential risks associated with using ctDNA as a biomarker or any possible limitations of this approach; lack of exploration into counterarguments; lack of detail on each side's arguments; and lack of promotional content which could indicate bias towards one side or another.

# Topics for further research:

* Risks associated with ctDNA biomarker
* Limitations of ctDNA biomarker
* Counterarguments to ctDNA biomarker
* Evidence for counterarguments to ctDNA biomarker
* Detailed arguments for and against ctDNA biomarker
* Promotional content related to ctDNA biomarker

# Report location:

<https://www.fullpicture.app/item/3d923748311b66836423f3282db1b3a5>